{
  "abstract": "Objectives: Anti-Ro52/TRIM21 antibodies have been linked to interstitial lung disease (ILD) severity in anti-synthetase syndrome (ASS), but their broader clinical relevance remains uncertain. We compared clinical, pulmonary, treatment, and outcome characteristics according to Anti-Ro52/TRIM21 status in a Swiss single-center cohort.\n\nMethods: This retrospective cohort included patients diagnosed with ASS followed at Geneva University Hospitals from 2010 to 2024 who met the Connors criteria and had available anti-Ro52 kDa antibody testing. Group comparisons used two-sided Wilcoxon rank-sum or Fisher’s exact tests, and exploratory associations were assessed using univariate Firth logistic regression.\n\nResults: Among 295 screened records, 38 patients were included (16 anti-Ro52/TRIM21-positive patients and 22 anti-Ro52/TRIM21-negative); mean follow-up was 6.63 ± 5.34 years. Pulmonary involvement was numerically more frequent in anti-Ro52/TRIM21-positive patients (15/16 [93.8%] vs 17/22 [77.3%]; p = 0.37), but the regression association was not statistically significant (OR 3.27, 95% CI 0.66–24.51; p = 0.18). Severe infections occurred in 6/16 (37.5%) versus 1/22 (4.5%) patients (p = 0.028); the univariate OR was 12.60 (95% CI 1.82–255.43; p = 0.027). Baseline DLCO and FVC were similar between the groups (p = 0.598 and p = 0.824, respectively). Treatment patterns differed descriptively, including greater use of biologic in some treatment lines among anti-Ro52/TRIM21-positive patients.\n\nConclusions: In this small exploratory cohort, severe infections were more frequent among anti-Ro52/TRIM21-positive patients in unadjusted analyses, whereas pulmonary involvement differed only numerically and baseline pulmonary function was similar. Treatment-related confounding factors and the imprecise infection estimate limit interpretation. Larger multicenter studies with standardized longitudinal pulmonary assessment and appropriately adjusted analyses accounting for treatment exposure are needed. Key Points\n\n• Pulmonary involvement was numerically more frequent in anti-Ro52/TRIM21-positive patients, but the difference was not statistically significant.\n\n• Severe infections were more frequent in anti-Ro52/TRIM21-positive patients in unadjusted analyses, but the estimate was imprecise and potentially confounded by treatment exposure.\n\n• Baseline muscle involvement, DLCO, FVC, and prednisone doses at measured time points were broadly similar between the groups.\n\n• Differences in steroid-sparing treatment patterns were descriptive but should not be interpreted as evidence of a distinct or more severe disease course.",
  "abstract_shown": true,
  "affiliations": [
    "Faculty of Medicine, University of Geneva, Geneva, Switzerland",
    "Biomedical Data Science Facility, University of Geneva, Geneva, Switzerland",
    "SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland",
    "Division of Immunology and Allergy, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, CH-1211 Geneva, Switzerland"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 3,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Vanessa Oliveira Teixeira"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Tania Wyss"
    },
    {
      "affs": [
        3
      ],
      "name": "Peter Jandus",
      "orcid": "0000-0002-2143-7856"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7agyta01wwpfh.bib",
  "cited_by": 0,
  "doi": "10.1007/s10067-026-08377-4",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13723650/",
  "id": "7agyta01wwpfh",
  "issns": [
    "0770-3198",
    "1434-9949"
  ],
  "landing_url": "https://doi.org/10.1007/s10067-026-08377-4",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2713|Inflammatory Myopathies and Dermatomyositis"
    ]
  ],
  "openalex": "W7211971873",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s10067-026-08377-4.pdf",
  "pmcid": "PMC13723650",
  "pmid": "42709299",
  "published": "2026-09-08",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7agyta01wwpfh.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:22:14Z",
      "native_id": "PMC13723650",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s10067-026-08377-4"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Inflammatory Myopathies and Dermatomyositis",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Clinical characteristics of anti-Ro52/TRIM21-positive versus anti-Ro52/TRIM21-negative patients with anti-synthetase syndrome: a retrospective cohort study",
  "title_text": "Clinical characteristics of anti-Ro52/TRIM21-positive versus anti-Ro52/TRIM21-negative patients with anti-synthetase syndrome: a retrospective cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:20:25Z",
  "url": "https://research.draconitic.com/paper/7agyta01wwpfh",
  "venue": "Clinical Rheumatology",
  "versions": []
}